Literature DB >> 7684029

Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.

C Ferri1, A L Zignego, G Longombardo, M Monti, L La Civita, F Lombardini, F Greco, A Mazzoni, G Pasero, P Gentilini.   

Abstract

Since a striking association between hepatitis C virus (HCV) infection and mixed cryoglobulinemia has been demonstrated, the aim of this study is to investigate the effect of alpha-interferon (alpha-IFN) on HCV viraemia and clinico-serological manifestations of 15 patients (ten female and five male, mean [+/- SD] age 53 +/- 7 years). In 14/15 patients pre-study steroid dosage remained unchanged during treatment. alpha-IFN was administered at a dose of 2 x 10(6) IU daily for a month, then every other day for five months. On the whole, a statistically significant improvement of purpura (p < 0.001), serum transaminases (p < 0.001), and cryocrit (p < 0.01) was observed after alpha-IFN treatment. HCV viraemia was detected by polymerase chain reaction technique in 13/15 patients with mixed cryoglobulinemia and anti-GOR antibodies, expression of HCV-related autoimmunity, were present in 8/15. After alpha-IFN treatment, HCV RNA levels showed a clear-cut reduction in five persons and disappeared in another, while anti-HCV antibodies (Chiron ELISA and RIBA II) did not change after the six-month period of therapy. These data further support the possible etiopathogenetic role of HCV in patients with mixed cryoglobulinemia and suggest that alpha-IFN may be regarded as the elective treatment in this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684029     DOI: 10.1007/bf01710739

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  33 in total

1.  Hepatitis C virus in patients with cryoglobulinemia type II.

Authors:  M Pascual; L Perrin; E Giostra; J A Schifferli
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

2.  Cryoglobulinaemia and hepatitis C virus.

Authors:  M Casato; G Taliani; L P Pucillo; F Goffredo; B Laganà; L Bonomo
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

3.  Antibodies against hepatitis C virus in mixed cryoglobulinemia patients.

Authors:  C Ferri; F Greco; G Longombardo; P Palla; A Moretti; E Marzo; P V Fosella; G Pasero; S Bombardieri
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

4.  Association between hepatitis C virus and mixed cryoglobulinemia [see comment].

Authors:  C Ferri; F Greco; G Longombardo; P Palla; A Moretti; E Marzo; A Mazzoni; G Pasero; S Bombardieri; P Highfield
Journal:  Clin Exp Rheumatol       Date:  1991 Nov-Dec       Impact factor: 4.473

5.  Cryoglobulins and immune complexes in essential mixed cryoglobulinemia.

Authors:  S Bombardieri; C Ferri; P Migliorini; A Pontrandolfo; A Puccetti; C Vitali; G Pasero
Journal:  Ric Clin Lab       Date:  1986 Apr-Jun

6.  Plasma-exchange in mixed cryoglobulinemia. Effects on renal, liver and neurologic involvement.

Authors:  C Ferri; G Gremignai; S Bombardieri; L Moriconi; A Pontrandolfo; C Vitali; P V Fosella; G Pasero
Journal:  Ric Clin Lab       Date:  1986 Apr-Jun

7.  Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity.

Authors:  M Lenzi; P J Johnson; I G McFarlane; G Ballardini; H M Smith; B M McFarlane; C Bridger; D Vergani; F B Bianchi; R Williams
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

8.  Antibodies to extractable nuclear antigens in 173 patients with DNA-binding positive SLE: an association between antibodies to ribonucleoprotein and Sm antigens observed by counterimmunoelectrophoresis.

Authors:  C C Bunn; A E Gharavi; G R Hughes
Journal:  J Clin Lab Immunol       Date:  1982-05

9.  Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon.

Authors:  M Shindo; A M Di Bisceglie; J H Hoofnagle
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

Review 10.  Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.

Authors:  P D Gorevic; H J Kassab; Y Levo; R Kohn; M Meltzer; P Prose; E C Franklin
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  5 in total

Review 1.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

Review 2.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 3.  Hepatitis C virus-related lymphoproliferative disorders: an overview.

Authors:  Anna-Linda Zignego; Carlo Giannini; Clodoveo Ferri
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

4.  Deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a.

Authors:  I Bojić; D Lilić; C Radojcić; P Mijusković
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

Review 5.  A role for chronic hepatitis C virus infection in a patient with cutaneous vasculitis, cryoglobulinemia, and chronic liver disease. Effective therapy with interferon-alpha.

Authors:  C A Schirren; R Zachoval; C G Schirren; A L Gerbes; G R Pape
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.